Superior Cervical Ganglion Block, Transcranial Doppler

Status Completed

Clinical Trial Summary

The aim of this study is to assess blood flow velocity in middle cerebral artery measured by transcranial doppler to determine the efficacy of SCG block in decreasing incidence or severity of vasospasm after MCA aneurysm surgery.

Clinical Trial Description

Sympathetic innervation to the face and head is by superior cervical ganglion(SCG), which is the most cranial part of the sympathetic chain. It is suited in a plication of the prevertebral fascia anterior to the longuscapitis muscle and dorsal to the internal carotid artery, posteromedial to the vagus nerve at c3 level. It's mainly located at the level of the transverse processes of the second and third cervical vertebrae. However, it may reach caudally to the upper border of the fourth cervical vertebra. Noradrenergic sympathetic nerve fibers mainly originating in the superior cervical ganglion, accompanying the carotid artery supply cerebral vasculature particularly the pial vessels. Superior cervical ganglion block was previously tried in managing neuropathic pain, neuropathic pain in head and face region was investigated in patients using ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion (SCG) ,The short-term analgesic effect of the first blockade by GLOA was significant with a mean pain reduction of 52% (p < 0.001). Superior cervical ganglion block also used as an alternative treatment to tinnitus not responding to conventional therapy, it increases cholear blood flow and this can explain the efficacy of block. Superior cervical ganglion block was used to improve cerebral perfusion in patients with cerebral vasospasm after aSAH. Aneurysmal subarachnoid hemorrhage (aSAH) may develop vasospasm in 70% of patients. Morphological changes occur in the cerebral vessels after SAH, and the inflammatory response and local chemical agents are responsible for the induction of vasospasm. Vasospasm is rare in the first 3 days after SAH, it reaches peak incidence at 7 to10 days and usually resolves by 10 to14 days after SAH. The sympathetic system also has a role in the pathogenesis of this process, cervical sympathetic stimulation leads to constriction in intracerebral vessels and dilation occurs when these fibers are interrupted. Efflux and reuptake of the neurotransmitter may be prevented by sympathectomy. Common treatments to reduce vasospasm include ;triple H therapy (hypertension ,hypervolemia and hemodilution), intraarterial infusion of Smooth muscle relaxants (papaverine, Verapamil) and endovascular balloon angioplasty . Also (nimodipine) calcium channel blocker administration is used as a prophylactic measures. Transcranial doppler (TCD) is a non-invasive technique which can be used to observe velocity, direction and properties of blood flow in the cerebral arteries by means of a pulsed ultrasonic beam, based on the Doppler effect of ultrasounds concerning frequency variations in sound waves as a result of relative motion between source and signal receiver. It was previously used in traumatic brain injury(TBI),stroke, anesthesia and intensive care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04439760
Study type	Interventional
Source	Kasr El Aini Hospital
Contact
Status	Completed
Phase	N/A
Start date	October 1, 2020
Completion date	July 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02345395` - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms	N/A
Active, not recruiting	`NCT05626504` - Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Completed	`NCT01716117` - Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms	N/A
Completed	`NCT04553549` - Safety and Feasibility of the Infinity Catheter for Radial Access
Completed	`NCT01975233` - WEB French Observatory of the WEB Aneurysm Embolization System
Terminated	`NCT01557036` - Aneurysm Study of Pipeline in an Observational Registry	N/A
Completed	`NCT02435823` - Safety Study of the PulseRider® in Patients Undergoing Treatment for Bifurcation Intracranial Aneurysms	N/A
Completed	`NCT03844334` - CLinical EValuation of WEB 0.017 Device in Intracranial AneuRysms
Active, not recruiting	`NCT03852680` - Current Treatment Modalities for Wide Necked Intracranial Aneurysms	N/A
Completed	`NCT01444664` - Aneurysm Wall Histology Registry	Phase 4
Recruiting	`NCT03936647` - The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices	N/A
Completed	`NCT02687607` - CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms
Withdrawn	`NCT02037932` - Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry	Phase 4
Recruiting	`NCT05317169` - Aneurysm Genetic Risk in Patients With QIB Changes
Terminated	`NCT00537134` - Trial on Endovascular Aneurysm Management	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.